万泰生物双价人乳头瘤病毒疫苗（大肠埃希菌）入围国家免疫规划疫苗集中采购项目，入围单价27.5元

Core Viewpoint - WanTai BioPharmaceutical (万泰生物) announced that its wholly-owned subsidiary, Xiamen WanTai Canghai Biotechnology Co., Ltd., has participated in the bidding for the 2025 National Immunization Program vaccine centralized procurement project for the bivalent human papillomavirus vaccine, successfully securing a bid price of 27.5 yuan [1] Group 1: Company Developments - The bivalent human papillomavirus vaccine (E. coli) has been shortlisted in the procurement project organized by the Chinese Center for Disease Control and Prevention [1] - If the company signs the procurement contract and organizes production and supply, it will help expand the sales scale of the shortlisted product [1] - This development is expected to enhance the company's market share and promote the domestic market expansion of the shortlisted product, thereby increasing the company's brand influence [1]